1
|
Versele M, del Pino Garcia J, Vandecaetsbeek I, Castermans K, Kellens R, Haeck W, Klaassen H, Bourin A, De Clercq D, Allasia S, Boland S, Marchand A, Chaltin P, Bollen M. Abstract 53: Discovery of novel potent and orally bioavailable small-molecule inhibitors of ENPP1 to stabilize cGAMP and ATP in the tumor microenvironment and boost anti-tumor immunity. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Extracellular 2',3'-cyclic GMP-AMP (cGAMP) has a critical immune-transmitter role in the tumor microenvironment (TME). Tumor cells produce and secrete cGAMP, which primes immune cells for tumor rejection through STING (stimulator of interferon genes) signalling (Marcus et al., Immunity 2018; Carozza et al., Nature Cancer 2020). Ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) is the only enzyme known to hydrolyze extracellular cGAMP. In concert with the ectoATPase CD39 and the 5'-nucleotidase CD73, ENPP1 also contributes to the generation of an immunosuppressive TME by converting extracellular ATP into adenosine. ENPP1 is overexpressed in a number of tumor types, including breast cancer, liver cancer, thyroid cancer and sarcomas, and has been associated with poor outcome. Hence, inhibition of ENPP1 is an emerging strategy to augment anti-tumor immunity by stabilizing extracellular cGAMP and ATP, thereby turning cold tumors into immunologically hot tumors. Here, we report on the identification and characterization of novel chemical series of ENPP1 inhibitors. A drug-like small-molecule library (~160,000 compounds) was screened to identify inhibitors of ENPP1-mediated cGAMP hydrolysis. Hits were confirmed to also inhibit ATP hydrolysis by ENPP1, but not nucleotide hydrolysis mediated by the closely related ENPP2 (autotaxin) enzyme. A selection of hits, chemically distinct from previously reported ENPP1 inhibitors (such as those based on QS1; Carroza et al, Cell Chem Biol, 2020), were subjected to hit-to-lead optimization supported by structure-based guidance. This led to the identification of ENPP1 inhibitors with sub-nM potency on ENPP1 in biochemical assays, which maintained a >1000x selectivity window with respect to ENPP2 and to other phosphodiesterases. These compounds translated well to stabilization of nucleotides in the presence of ENPP1-overexpressing cancer cell lines, with IC50 values in the nM range. A selection of compounds was profiled for DMPK (drug metabolism and pharmacokinetic) parameters, and compounds with a suitable profile were prioritized for in vivo evaluation. Orally bio-available, metabolically stable compounds were assessed in mouse syngeneic tumor models, selected on the basis of high ENPP1 and high cGAS (cGAMP synthase) expression. Stabilization of cGAMP, activation of a STING-mediated cytokine response and immune-cell infiltration/activation in the TME were used as pharmacodynamic endpoints. An update on in vivo efficacy data in a range of ENPP1-positive tumor models will be provided during the presentation. These novel orally bioavailable ENPP1 inhibitors unleash local, TME-restricted, innate immune activation, and hold the promise to overcome the current limitations of direct STING agonists.
Citation Format: Matthias Versele, Javier del Pino Garcia, Ilse Vandecaetsbeek, Karolien Castermans, Ranie Kellens, Wanda Haeck, Hugo Klaassen, Arnaud Bourin, Dries De Clercq, Sara Allasia, Sandro Boland, Arnaud Marchand, Patrick Chaltin, Mathieu Bollen. Discovery of novel potent and orally bioavailable small-molecule inhibitors of ENPP1 to stabilize cGAMP and ATP in the tumor microenvironment and boost anti-tumor immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 53.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | - Patrick Chaltin
- 3Center for Drug Design and Discovery (CD3), Leuven, Belgium
| | | |
Collapse
|
2
|
Caillaud D, Annesi-Maesano I, Bourin A, Chinet T, Colette A, De Blay F, Dixsaut G, Housset B, Kleinpeter J, Malherbe L, Roussel I, Dalphin JC, Charpin D. [Outdoor pollution and its effects on lung health in France. Expert document from the Groupe Pathologies pulmonaires professionnelles environnementales et iatrogéniques (PAPPEI) of the Société de pneumologie de langue française (SPLF)]. Rev Mal Respir 2019; 36:1150-1183. [PMID: 31676143 DOI: 10.1016/j.rmr.2019.10.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- D Caillaud
- Service de pneumologie, CHU Clermont-Ferrand, Inra, université Clermont Auvergne, 63000 Clermont-Ferrand, France.
| | - I Annesi-Maesano
- Sorbonne universités, UPMC Univ Paris 06, Inserm, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP UMR S 1136), épidémiologie des maladies allergiques et respiratoires, faculté de médecine Saint-Antoine, 75012 Paris, France
| | - A Bourin
- Sciences de l'atmosphère et génie de l'environnement, IMT, Lille, 59650 Douai, France
| | - T Chinet
- Service de pneumologie et oncologie thoracique, CHU Ambroise-Paré, université de Versailles SQY, 92100 Boulogne-Billancourt, France
| | - A Colette
- Unité de modélisation atmosphérique et de cartographie environnementale, INERIS, 60550 Verneuil-en-Halatte, France
| | - F De Blay
- Pôle de pathologie thoracique, hôpitaux universitaires de Strasbourg, Fédération de médecine translationnelle, université de Strasbourg, 67000 Strasbourg , France
| | - G Dixsaut
- Service de physiologie explorations fonctionnelles, hôpital Cochin Hôtel Dieu et Fondation du Souffle contre les maladies respiratoires, 75014 Paris, France
| | - B Housset
- Service de pneumologie et pathologie professionnelle, centre hospitalier intercommunal de Créteil, département hospitalo-universitaire A-TVB, unité Inserm 955, Institut santé travail Paris-Est, université Paris-Est, 94000 Créteil, France
| | - J Kleinpeter
- Association agréée de Surveillance de la qualité de l'Air de la région Grand Est (ATMO Grand Est), 5, rue de Madrid, 67300 Schiltigheim, France; Association de surveillance de la pollution atmosphérique en Alsace (ASPA), 5, rue de Madrid, 67300 Schiltigheim, France
| | - L Malherbe
- Unité de modélisation atmosphérique et de cartographie environnementale, INERIS, 60550 Verneuil-en-Halatte, France
| | - I Roussel
- Faculté de Lille, 59000 Lille, France
| | - J-C Dalphin
- Service de pneumologie, CHU de Besançon, UMR CNRS 6249 chrono-environnement, université de Franche-Comté, 25000 Besançon, France
| | - D Charpin
- Unité de pneumologie, groupe hospitalier de la Timone, Aix-Marseille université et Association pour la prévention de la pollution atmosphérique, 13000 Marseille, France
| | | |
Collapse
|
3
|
Holvoet T, Devriese S, Castermans K, Boland S, Leysen D, Vandewynckel YP, Devisscher L, Van den Bossche L, Van Welden S, Dullaers M, Vandenbroucke RE, De Rycke R, Geboes K, Bourin A, Defert O, Hindryckx P, De Vos M, Laukens D. Treatment of Intestinal Fibrosis in Experimental Inflammatory Bowel Disease by the Pleiotropic Actions of a Local Rho Kinase Inhibitor. Gastroenterology 2017. [PMID: 28642198 DOI: 10.1053/j.gastro.2017.06.013] [Citation(s) in RCA: 86] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
BACKGROUND Intestinal fibrosis resulting in (sub)obstruction is a common complication of Crohn's disease (CD). Rho kinases (ROCKs) play multiple roles in TGFβ-induced myofibroblast activation that could be therapeutic targets. Because systemic ROCK inhibition causes cardiovascular side effects, we evaluated the effects of a locally acting ROCK inhibitor (AMA0825) on intestinal fibrosis. METHODS Fibrosis was assessed in mouse models using dextran sulfate sodium (DSS) and adoptive T-cell transfer. The in vitro and ex vivo effects of AMA0825 were studied in different cell types and in CD biopsy cultures. RESULTS ROCK is expressed in fibroblastic, epithelial, endothelial, and muscle cells of the human intestinal tract and is activated in inflamed and fibrotic tissue. Prophylactic treatment with AMA0825 inhibited myofibroblast accumulation, expression of pro-fibrotic factors, and accumulation of fibrotic tissue without affecting clinical disease activity and histologic inflammation in 2 models of fibrosis. ROCK inhibition reversed established fibrosis in a chronic DSS model and impeded ex vivo pro-fibrotic protein secretion from stenotic CD biopsies. AMA0825 reduced TGFβ1-induced activation of myocardin-related transcription factor (MRTF) and p38 mitogen-activated protein kinase (MAPK), down-regulating matrix metalloproteinases, collagen, and IL6 secretion from fibroblasts. In these cells, ROCK inhibition potentiated autophagy, which was required for the observed reduction in collagen and IL6 production. AMA0825 did not affect pro-inflammatory cytokine secretion from other ROCK-positive cell types, corroborating the selective in vivo effect on fibrosis. CONCLUSIONS Local ROCK inhibition prevents and reverses intestinal fibrosis by diminishing MRTF and p38 MAPK activation and increasing autophagy in fibroblasts. Overall, our results show that local ROCK inhibition is promising for counteracting fibrosis as an add-on therapy for CD.
Collapse
Affiliation(s)
- Tom Holvoet
- Department of Gastroenterology, Ghent University, Ghent, Belgium
| | - Sarah Devriese
- Department of Gastroenterology, Ghent University, Ghent, Belgium
| | | | | | | | | | | | | | | | - Melissa Dullaers
- Inflammation Research Center, VIB, Ghent, Belgium; Department of Pulmonary Medicine, Ghent University, Ghent, Belgium
| | - Roosmarijn E Vandenbroucke
- Inflammation Research Center, VIB, Ghent, Belgium; Department of Molecular Biomedical Research, Ghent University, Ghent, Belgium
| | - Riet De Rycke
- Inflammation Research Center, VIB, Ghent, Belgium; Department of Molecular Biomedical Research, Ghent University, Ghent, Belgium
| | - Karel Geboes
- Department of Pathology, Ghent University, Ghent, Belgium
| | | | | | - Pieter Hindryckx
- Department of Gastroenterology, Ghent University, Ghent, Belgium
| | - Martine De Vos
- Department of Gastroenterology, Ghent University, Ghent, Belgium
| | - Debby Laukens
- Department of Gastroenterology, Ghent University, Ghent, Belgium.
| |
Collapse
|
4
|
Alen J, Bourin A, Boland S, Geraets J, Schroeders P, Defert O. Tetrahydro-pyrimido-indoles as selective LIMK inhibitors: synthesis, selectivity profiling and structure–activity studies. Med Chem Commun 2016. [DOI: 10.1039/c5md00473j] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Extensive structure–activity studies on three different modification sites resulted in a series of LIM kinase inhibitors, containing a novel tricyclic hinge-binding motif based on the pyrrolopyrimidine scaffold.
Collapse
Affiliation(s)
- J. Alen
- Amakem Therapeutics
- Agoralaan Abis
- 3590 Diepenbeek
- Belgium
| | - A. Bourin
- Amakem Therapeutics
- Agoralaan Abis
- 3590 Diepenbeek
- Belgium
| | - S. Boland
- Amakem Therapeutics
- Agoralaan Abis
- 3590 Diepenbeek
- Belgium
| | - J. Geraets
- Amakem Therapeutics
- Agoralaan Abis
- 3590 Diepenbeek
- Belgium
| | - P. Schroeders
- Amakem Therapeutics
- Agoralaan Abis
- 3590 Diepenbeek
- Belgium
| | - O. Defert
- Amakem Therapeutics
- Agoralaan Abis
- 3590 Diepenbeek
- Belgium
| |
Collapse
|
5
|
Boland S, Bourin A, Alen J, Geraets J, Schroeders P, Castermans K, Kindt N, Boumans N, Panitti L, Fransen S, Vanormelingen J, Stassen JM, Leysen D, Defert O. Design, Synthesis, and Biological Evaluation of Novel, Highly Active Soft ROCK Inhibitors. J Med Chem 2015; 58:4309-24. [DOI: 10.1021/acs.jmedchem.5b00308] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- Sandro Boland
- Amakem Therapeutics, Agoralaan
Abis, 3590 Diepenbeek, Belgium
| | - Arnaud Bourin
- Amakem Therapeutics, Agoralaan
Abis, 3590 Diepenbeek, Belgium
| | - Jo Alen
- Amakem Therapeutics, Agoralaan
Abis, 3590 Diepenbeek, Belgium
| | - Jacques Geraets
- Amakem Therapeutics, Agoralaan
Abis, 3590 Diepenbeek, Belgium
| | | | | | - Nele Kindt
- Amakem Therapeutics, Agoralaan
Abis, 3590 Diepenbeek, Belgium
| | - Nicki Boumans
- Amakem Therapeutics, Agoralaan
Abis, 3590 Diepenbeek, Belgium
| | - Laura Panitti
- Amakem Therapeutics, Agoralaan
Abis, 3590 Diepenbeek, Belgium
| | - Silke Fransen
- Amakem Therapeutics, Agoralaan
Abis, 3590 Diepenbeek, Belgium
| | | | | | - Dirk Leysen
- CSD Farmakem, Elvire Boelensstraat
7, 9160 Lokeren, Belgium
| | - Olivier Defert
- Amakem Therapeutics, Agoralaan
Abis, 3590 Diepenbeek, Belgium
| |
Collapse
|
6
|
Boland S, Alen J, Bourin A, Castermans K, Boumans N, Panitti L, Vanormelingen J, Leysen D, Defert O. Novel Roflumilast analogs as soft PDE4 inhibitors. Bioorg Med Chem Lett 2014; 24:4594-4597. [PMID: 25149511 DOI: 10.1016/j.bmcl.2014.07.016] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2014] [Revised: 07/05/2014] [Accepted: 07/07/2014] [Indexed: 11/19/2022]
Abstract
PDE4 inhibitors are of high interest for treatment of a wide range of inflammatory or autoimmune diseases. Their potential however has not yet been realized due to target-associated side effects, resulting in a low therapeutic window. We herein report the design, synthesis and evaluation of novel PDE4 inhibitors containing a γ-lactone structure. Such molecules are designed to undergo metabolic inactivation when entering circulation, thereby limiting systemic exposure and reducing the risk for side effects. The resulting inhibitors were highly active on both PDE4B1 and PDE4D2 and underwent rapid degradation in human plasma by paraoxonase 1. In contrast, their metabolites displayed markedly reduced permeability and/or on-target activity.
Collapse
Affiliation(s)
- Sandro Boland
- Amakem N.V. Agoralaan A bis, 3590 Diepenbeek, Belgium.
| | - Jo Alen
- Amakem N.V. Agoralaan A bis, 3590 Diepenbeek, Belgium
| | - Arnaud Bourin
- Amakem N.V. Agoralaan A bis, 3590 Diepenbeek, Belgium
| | | | - Nicki Boumans
- Amakem N.V. Agoralaan A bis, 3590 Diepenbeek, Belgium
| | - Laura Panitti
- Amakem N.V. Agoralaan A bis, 3590 Diepenbeek, Belgium
| | | | - Dirk Leysen
- Amakem N.V. Agoralaan A bis, 3590 Diepenbeek, Belgium
| | | |
Collapse
|
7
|
Boland S, Defert O, Alen J, Bourin A, Castermans K, Kindt N, Boumans N, Panitti L, Van de Velde S, Stalmans I, Leysen D. 3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors. Bioorg Med Chem Lett 2013; 23:6442-6. [DOI: 10.1016/j.bmcl.2013.09.040] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2013] [Revised: 09/12/2013] [Accepted: 09/13/2013] [Indexed: 12/15/2022]
|
8
|
Beghyn TB, Charton J, Leroux F, Laconde G, Bourin A, Cos P, Maes L, Deprez B. Drug to genome to drug: discovery of new antiplasmodial compounds. J Med Chem 2011; 54:3222-40. [PMID: 21504142 DOI: 10.1021/jm1014617] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The dominant strategy for discovery of new antimalarial drugs relies on cell-free assays on specific biochemical pathways of Plasmodium falciparum . However, it appears that screening directly on the parasite is a more rewarding approach. The "drug to genome to drug" approach consists of testing a small set of structural analogues of a drug acting on human proteins that have plasmodial orthologues. Both man and plasmodium possess cyclic nucleotide phosphodiesterases (PDEs) that are key players of cell homeostasis. We synthesized and tested 40 analogues of tadalafil, a human PDE5 inhibitor, on P. falciparum in culture and obtained potent inhibitors of parasite growth. We discuss the structure-activity relationships, which support the hypothesis that our compounds kill the parasite via inhibition of plasmodial PDE activity. We also prove that antiplasmodial derivatives inhibit the hydrolysis of cyclic nucleotides of the parasite, validating the cAMP/cGMP pathways as therapeutic targets against Plasmodium falciparum.
Collapse
Affiliation(s)
- Terence B Beghyn
- INSERM U761 Biostructures and Drug Discovery, Faculté de Pharmacie, Université Lille Nord de France, Institut Pasteur de Lille, and Pôle de Recherche Interdisciplinaire pour le Médicament , Lille F-59000, France
| | | | | | | | | | | | | | | |
Collapse
|
9
|
de Lemos E, Porée FH, Bourin A, Barbion J, Agouridas E, Lannou MI, Commerçon A, Betzer JF, Pancrazi A, Ardisson J. Total synthesis of discodermolide: optimization of the effective synthetic route. Chemistry 2009; 14:11092-112. [PMID: 18973162 DOI: 10.1002/chem.200801478] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
An efficient and modulable total synthesis of discodermolide (DDM), a unique marine anticancer polyketide is described including related alternative synthetic approaches. Particularly notable is the repeated application of a crotyltitanation reaction to yield homoallylic (Z)-O-ene-carbamate alcohols with excellent selectivity. Advantage was taken of this reaction not only for the stereocontrolled building of the syn-anti methyl-hydroxy-methyl triads of DDM, but also for the direct construction of the terminal (Z)-diene. Of particular interest is also the installation of the C13=C14 (Z)-double bond through a highly selective dyotropic rearrangement. The preparation of the middle C8-C14 fragment in two sequential stages and its coupling to the C1-C7 moiety was a real challenge and required careful optimization. Several synthetic routes were explored to allow high and reliable yields. Due to the flexibility and robust character of this approach, it might enable a systematic structural variation of DDM and, therefore, the elaboration and exploration of novel discodermolide structural analogues.
Collapse
Affiliation(s)
- Elsa de Lemos
- Université Paris Descartes, Faculté de Pharmacie, CNRS UMR 8638, 4 avenue de l'Observatoire, 75270 Paris Cedex, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Dhulut S, Bourin A, Lannou MI, Fleury E, Lensen N, Chelain E, Pancrazi A, Ardisson J, Fahy J. Cyclic Allyl Carbamates in Stereoselectivesyn SE′ Processes: Synthetic Approach to Sarcodictyins and Eleutherobin. European J Org Chem 2007. [DOI: 10.1002/ejoc.200700490] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|